Boryung wins the Pomalyst patent challenge for the 2nd time
By Kim, Jin-Gu | translator Kang, Shin-Kook
24.06.11 05:05:00
가나다라
0
Despite winning patent avoidance in 2021, the company filed claims to confirm the scope of a right again
Seems like the development method had changed…finished applying for approval of generics and may secure a priority sale
▲Boryung has once again challenged the Pomalyst patent and won.
Boryung won the second attempt to avoid the substance patent of ‘Pomalyst (pomalidomide),‘ a treatment for multiple myeloma.Despite winning the infringement trial for the same patent in 2021, Boryung had not released generic versions. It seems that Boryung changed the method of generic development and rechallenged the patent.
The analysis suggests that Boryung is on a countdown to releasing Pomalyst generic following the second-time success of the patent infringement challenge. It has been confirmed that Boryung has already applied for marketing approval for four doses of pomalidomide.
According to pharmaceutical industry sources on June 10th, Boryung received the decis
Kim, Jin-Gu(kjg@dailypharm.com)
If you want to see the full article, please JOIN US (click)